Navigation Links
ActivBiotics Outlines a Clinical Path Forward to Examine if Rifalazil Is Superior to Azithromycin in the Treatment of Chlamydia STD
Date:2/19/2008

WELLESLEY HILLS, Mass., Feb. 19 /PRNewswire/ -- Joseph F. Finn, Jr., CPA, the Assignee for the Benefit of Creditors of ActivBiotics, announced today the design of a clinical trial to investigate whether Chlamydia STD is treated adequately by currently approved antibiotics. Rifalazil, the most potent anti-chlamydial agent that has been administered to people, may provide a better treatment option for Chlamydia STD. The insidious aspect of Chlamydia STD is that infections which are inadequately treated can later result in serious consequences. A new, improved treatment would prevent the long-term detrimental effects of Chlamydia STD, which for women include mucopurulent cervicitis, pelvic inflammatory disease, ectopic pregnancy, and infertility. Chlamydia STD infections have also been associated with increased transmission of human immunodeficiency virus (HIV) in both men and women.

At the present time, the prevailing medical opinion is that Chlamydia STD is treated adequately by a single 1 gram oral dose of azithromycin. However, in a previous Phase II clinical trial (published in 2007 in the journal Sexually Transmitted Diseases), men experiencing symptoms of nongonococcal urethritis attributed to Chlamydia trachomatis infection had higher cure rates with rifalazil than with azithromycin five weeks after treatment. Although the sample size of the trial was small, these results certainly left room to consider the possibility of an improved therapy with rifalazil for treating all Chlamydia STDs.

The new trial would compare a group of women, all infected with Chlamydia STD, who would be administered a single oral dose of rifalazil with a similar group receiving a single dose of azithromycin. "We can examine if rifalazil is superior to azithromycin in eradicating Chlamydia STD in women by evaluating 55 subjects in each treatment group", said Walter Stamm from the University of Washington, a leading clinician in the area of Chlamydia STD. Indeed, such a result would be welcome news to the million women in the US infected with Chlamydia STD according the Centers for Disease Control and Prevention.

The sale of ActivBiotics' assets, including rifalazil, is being conducted through an Assignment for the Benefit of Creditors. The bidding for the assets, which may be purchased separately or in combination, is scheduled for March 14, 2008.

For additional information on the terms of sale and to obtain a bidder's package, please contact Joseph F. Finn, Jr., CPA (jffinnjr@earthlink.net, phone 781-237-8840), Finn, Warnke & Gayton, 167 Worcester Street, Suite 201, Wellesley Hills, MA 02481-3613. For technical information on the assets, please contact Christo Shalish, cshalish@activbiotics.com.


'/>"/>
SOURCE ActivBiotics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. ActivBiotics Receives Orphan Drug Designation from the European Medicines Agency for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis Indication
2. ActivBiotics to Present Results of Pivotal Study in the Treatment of Peripheral Arterial Disease at AHA Meeting
3. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
4. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
5. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
6. First Clinical Volumetric Modulated Arc Therapy Treatment Completed With Elekta Synergy(R) S at General Hospital Vienna
7. Preliminary PI-88 Phase 2 Prostate Cancer Results to be Presented at the American Society for Clinical Oncology (ASCO) 2008 Genitourinary Cancer Symposium
8. Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
9. Maine Natural Health Company Conducts Dental Clinical Trial
10. Clinical Update - Decapeptyl(R)/Trelstar(R) 6-Month Formulation in Advanced Prostate Cancer
11. AGI Dermatics Clinical Data Indicate Bicyclic Monoterpene Diols Suppress MMP1 and Stimulate Collagen Through TNF-a Signaling
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)...   National Community Pharmacists Association (NCPA) CEO ... following statement today in response to the detailed "preferred ... for Medicare & Medicaid Services (CMS) and conducted in ... others: patient advocacy organizations and members ... full CMS analysis. Our initial reaction is that more ...
(Date:2/12/2016)... Feb. 12, 2016 /PRNewswire/ - Demers Ambulances announces its first delivery ... Okaloosa County Emergency Medical Services (EMS) ... and one LT2 van. Quality Emergency Vehicles in ... for the sale.  This is the latest in Demers, ongoing ... Vice President at Demers. --> Benoit LaFortune , ...
(Date:2/12/2016)... , Feb. 12, 2016  Memorial Hermann Health System ... Dwight Howard to bring a one-of-a-kind experience to ... Using cutting-edge technologies such as 360-degree video and Google ... virtually, then literally – giving the patients and their ... it was all caught on video . ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... February 13, 2016 , ... ... Society (INS) states that vein visualization technology should be used to ensure patient ... around the world, the INS Standards mandate the use of vein visualization technology ...
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... ... Tech Outlook’s top Clinical Data Management Solution Providers list for its expertise in ... functional and domain expertise to serve the technology needs of global clients. DDi ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... Siemens Foundation-PATH Ingenuity Fellowships—to develop the advanced skills needed to introduce and ... U.S. universities who will draw from Siemens’ deep knowledge of product development ...
(Date:2/12/2016)... ... ... Each year, the American Physical Therapy Association (APTA) offers a Combined Sections Meeting. ... Almost 10,000 physical therapists across the country are expected to attend this annual convention ... field and network with their colleagues. As in years past, HydroWorx is proud ...
(Date:2/12/2016)... ... February 12, 2016 , ... The ThedaCare Center for Healthcare ... Hospital on April 5-7. The series is a multi-day, multi-workshop event designed to ... cover a broad range of topics, including coaching skills, the scientific method of ...
Breaking Medicine News(10 mins):